Whom to Biopsy Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators

被引：19
作者：
Loeb, Stacy [1 ,2 ,3 ]
Dani, Hasan [4 ]
机构：
[1] NYU, Dept Urol, New York, NY USA
[2] NYU, Dept Populat Hlth, New York, NY USA
[3] Manhattan Vet Affairs Med Ctr, Dept Urol, New York, NY USA
[4] SUNY, Downstate Coll Med, Dept Urol, Brooklyn, NY USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2017年 / 44卷 / 04期
关键词：
Prostate cancer; Prostate-specific antigen; Biomarkers; Prostate biopsy; Nomograms; PROSTATE HEALTH INDEX; CANCER ANTIGEN 3; MOLECULAR URINE ASSAY; HIGH-GRADE CANCER; RADICAL PROSTATECTOMY; CLINICAL-PERFORMANCE; INTERNAL VALIDATION; EXTERNAL VALIDATION; ACTIVE SURVEILLANCE; KALLIKREIN MARKERS;
D O I：
10.1016/j.ucl.2017.07.001
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
This article describes markers used for prostate biopsy decisions, including prostrate-specific antigen (PSA), free PSA, the prostate health index, 4Kscore, PCA3, and ConfirmMDx. It also summarizes the use of nomograms combining multiple variables for prostate cancer detection.
引用
收藏
页码：517 / +
页数：9
相关论文
共 50 条
  • [21] Biomarkers for risk stratification of neoplastic progression in Barrett esophagus
    Kerkhof, Marjon
    Kusters, Johannes G.
    van Dekken, Herman
    Kuipers, Ernst J.
    Siersema, Peter D.
    CELLULAR ONCOLOGY, 2007, 29 (06) : 507 - 517
  • [22] Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer
    Eickelschulte, Samaneh
    Riediger, Anja Lisa
    Angeles, Arlou Kristina
    Janke, Florian
    Duensing, Stefan
    Sueltmann, Holger
    Goertz, Magdalena
    CANCERS, 2022, 14 (24)
  • [23] Percentage of Positive Biopsy Cores: A Better Risk Stratification Model for Prostate Cancer?
    Huang, Jiayi
    Vicini, Frank A.
    Williams, Scott G.
    Ye, Hong
    McGrath, Samuel
    Ghilezan, Mihai
    Krauss, Daniel
    Martinez, Alvaro A.
    Kestin, Larry L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04): : 1141 - 1148
  • [24] Risk Stratification for Acute Kidney Injury: Are Biomarkers Enough?
    McMahon, Blaithin A.
    Koyner, Jay L.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2016, 23 (03) : 167 - 178
  • [25] The Role of Inflammatory Biomarkers in the Pre-Biopsy Risk Stratification of Patients with Suspicious Mri Lesions of the Prostate: Where Should We Head?
    Giannakodimos, Ilias
    Moulavasilis, Napoleon
    Stravodimos, Konstantinos
    Fragkiadis, Evaggelos
    CURRENT MEDICINAL CHEMISTRY, 2024,
  • [26] Whom to Treat Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier
    Herlemann, Annika
    Washington, Samuel L., III
    Eapen, Renu S.
    Cooperberg, Matthew R.
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 547 - +
  • [27] Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome
    Pereira-Azevedo, Nuno
    Verbeek, Jan F. M.
    Nieboer, Daan
    Bangma, Chris H.
    Roobol, Monique J.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 (01) : 18 - +
  • [28] Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study
    Sandahl, Mads
    Pedersen, Bodil Ginnerup
    Ulhoi, Benedicte Parm
    Borre, Michael
    Sorensen, Karina Dalsgaard
    BJU INTERNATIONAL, 2021, 128 (06) : 702 - 712
  • [29] Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy
    Reesink, Daan J.
    Schilham, Melline G. M.
    van der Hoeven, Erik J. R. J.
    Schoots, Ivo G.
    van Melick, Harm H. E.
    van den Bergh, Roderick C. N.
    WORLD JOURNAL OF UROLOGY, 2021, 39 (07) : 2453 - 2461
  • [30] Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy
    Daan J. Reesink
    Melline G. M. Schilham
    Erik J. R. J. van der Hoeven
    Ivo G. Schoots
    Harm H. E. van Melick
    Roderick C. N. van den Bergh
    World Journal of Urology, 2021, 39 : 2453 - 2461
12345